Kura Oncology GAAP EPS of -$0.92 misses by $0.18, revenue of $17.34M misses by $18.11M
Source: SeekingAlpha
2026-03-05 06:34:40 ET
More on Kura Oncology
- Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy
- Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML - Slideshow
- Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
- Kura Oncology Q4 2025 Earnings Preview
- Kura Oncology rises following Jim Cramer comments
Read the full article on Seeking Alpha
For further details see:
Kura Oncology GAAP EPS of -$0.92 misses by $0.18, revenue of $17.34M misses by $18.11M
Kura Oncology Inc.
NASDAQ: KURA
KURA Trading
0.27% G/L:
$9.405 Last:
510,995 Volume:
$9.48 Open:
KURA Latest News
March 06, 2026 07:30:00 am
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2026 06:31:00 am
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026 07:30:00 am
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
KURA Stock Data
$684,827,867
74,138,925
1.16%
63
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
